TELA BIO INC
TELANASDAQTrading Snapshot
- Day Range
- $0.79 – $0.81
- 52-Week Range
- $0.50 – $2.14
- Volume
- $2.96B
- Avg Volume
- $2.43B
- Shares Outstanding
- 44.8M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $80M
- Last Q Revenue
- $19M
- P/E Ratio
- —
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-0.80
- Dividend Yield
- —
Why Investors Own TELA
- ✓High-growth profile — revenue up +40.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About TELA BIO INC
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsLouisa Smith - Investor Relations Contact OfficerJoseph...
TELA Bio Q2 EPS $(0.20) Misses $(0.18) Estimate, Sales $19.291M Miss $20.008M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 9.09 percent increase over losses of $(0.22) per share from the
TELA Bio Appoints Heather Getz CEO, Effective Immediately
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors